New collaboration to focus on the ABCs of ETBs

Molecular Templates, Inc. and Alnylam Pharmaceuticals, Inc. have entered into a research collaboration focused on evaluating and developing Molecular Templates’ proprietary technology for the targeted delivery of RNAi therapies.

Register for free to listen to this article
Listen with Speechify
GEORGETOWN, Texas—Molecular Templates, Inc. and AlnylamPharmaceuticals, Inc. have entered into a research collaboration focused onevaluating and developing Molecular Templates' proprietary technology for thetargeted delivery of RNAi therapies. Molecular Templates' main focus is thediscovery and development of a class of small biologic therapies known asEngineered Toxin Bodies (ETB). Financial details regarding the collaborationwere not released.
ETBs are part of a class of therapies that have evolved froma toxin scaffold and have been engineered to display a unique targeting domainas well as reduced immunogenicity. They retain the pharmacokinetics,mechanism-of-action, abilitiy to induce internalization and intracellularself-routing capabilities to the parent scaffold, and their properties allowthem to target cell surface or intracellular targets.
Molecular Templates isengaged in the development of ETBs across a range of disease areas such as cancer,autoimmune and infectious diseases. Eric Poma, Ph.D., President and ChiefExecutive Officer of Molecular Templates, says ETBs "represent a new classof targeted biologics that possess active intracellular properties thatuniquely positions us to address delivery of RNAi drugs in a target directedmanner."
"We look forward to working closely with Alnylam, the leaderin the RNAi space, to capitalize on some of the unique capabilities of our ETBplatform," says Poma. 
SOURCE: Molecular Templates, Inc. press release

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN July 2024 Magazine Issue

Latest Issue  

• Volume 20 • Issue 4 • July 2024

July 2024

July 2024 Issue